CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
CIViC Variants/Mutation

Mutation

CIViC ID: 442 · Gene: EGFR

Variant Summary

HGVS
—
Variant Type(s)
inframe_variant
Evidence Items
17

Evidence Level Distribution

Level A: 2Level B: 14Level C: 1

Evidence Items

Showing CIViC evidence rows where gene = EGFR and variant = Mutation.

LevelTypeDirectionSignificanceDiseaseDrugsRating
BPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinib5
BPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinib5
APredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDatopotamab Deruxtecan Regimen4
APredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDatopotamab Deruxtecan4
BPrognosticSupportsBetter OutcomeLung Adenocarcinoma4
BPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAfatinib4
BPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,Gefitinib4
BPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAfatinib4
CPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib4
BPredictiveSupportsSensitivity/ResponsePeritoneal MesotheliomaCytoreductive Surgery,Hyperthermic Intraperitoneal Chemotherapy4
BPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib4
BPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinib3
BPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinib3
BPrognosticSupportsBetter OutcomeLung Adenocarcinoma3
BPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib3
BPredictiveSupportsSensitivity/ResponseLung CancerGefitinib2
BPredictiveSupportsSensitivity/ResponseLung CancerErlotinib2